Modalities of vision restoration in optic neuropathies and retinal disease
Abstract
Visual impairment affects over 250 million people globally and carries a significant psychosocial and economic burden. In recent years, rapid advancements in biomedical engineering and regenerative medicine have driven the development of innovative therapies aimed at restoring visual function. Here, we first provide an overview of the visual pathway, imaging modalities, and the psychosocial and economic burden of vision loss. Then we review four vision restoration approaches: gene and stem cell therapies, optogenetics, retinal prosthetic devices, and visual pathway electrical stimulation. For each therapeutic approach, the mechanism of action, clinical outcomes, adverse events, and current limitations are discussed. Stem cell transplantation and gene-editing technologies are being explored to repair or replace damaged retinal cells at the molecular level. Retinal prosthetics implanted in various layers of the retina induce visual experiences in patients with degenerative diseases, though challenges in resolution and long-term performance remain. Lastly, electrical stimulation techniques, including transcorneal and transorbital stimulation, have shown potential to enhance residual vision through neuroprotective measures and neuroplastic synchronization of neuronal signaling activity. This article reviews and compares these therapies to give a balanced perspective on treatment modalities for visual impairment in a range of retinal diseases and optic neuropathies.
Related
- Cell-autonomous restoration of splicing homeostasis and RP11 phenotype in patient-derived RPE and retinal organoids by PRPF31.AAV gene therapy
- Restoration of the Inner Blood–Retinal Barrier in Diabetic Retinopathy Through Norrin-FZD4 Signaling
- From Engraftment to Vision: Defining Evidence of Functional Success in Retinal Cell Replacement Therapy
- The First 40 Years of Molecular Ophthalmology Part One: Inherited Retinal Disease: The 2026 Friedenwald Lecture
- iPSC-derived RPE and retinal organoids from two phenotypically different Stargardt disease patients show differences in ABCA4 function
BibTeX
@article{rubin2026modalities,
title = {{Modalities of vision restoration in optic neuropathies and retinal disease}},
author = {Batsheva Rubin and Fabio Lavinsky and Rachel Cain and Ajay Kuriyan and Gadi Wollstein and Ronald Zambrano and Joel Schuman},
journal = {Progress in Retinal and Eye Research},
year = {2026},
month = oct,
doi = {10.1016/j.preteyeres.2026.101474},
url = {https://hal.science/hal-05791269v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Modalities of vision restoration in optic neuropathies and retinal disease
AU - Batsheva Rubin
AU - Fabio Lavinsky
AU - Rachel Cain
AU - Ajay Kuriyan
AU - Gadi Wollstein
AU - Ronald Zambrano
AU - Joel Schuman
PY - 2026
DA - 2026/10/10
JO - Progress in Retinal and Eye Research
DO - 10.1016/j.preteyeres.2026.101474
UR - https://hal.science/hal-05791269v1
AB - Visual impairment affects over 250 million people globally and carries a significant psychosocial and economic burden. In recent years, rapid advancements in biomedical engineering and regenerative medicine have driven the development of innovative therapies aimed at restoring visual function. Here, we first provide an overview of the visual pathway, imaging modalities, and the psychosocial and economic burden of vision loss. Then we review four vision restoration approaches: gene and stem cell therapies, optogenetics, retinal prosthetic devices, and visual pathway electrical stimulation. For each therapeutic approach, the mechanism of action, clinical outcomes, adverse events, and current limitations are discussed. Stem cell transplantation and gene-editing technologies are being explored to repair or replace damaged retinal cells at the molecular level. Retinal prosthetics implanted in various layers of the retina induce visual experiences in patients with degenerative diseases, though challenges in resolution and long-term performance remain. Lastly, electrical stimulation techniques, including transcorneal and transorbital stimulation, have shown potential to enhance residual vision through neuroprotective measures and neuroplastic synchronization of neuronal signaling activity. This article reviews and compares these therapies to give a balanced perspective on treatment modalities for visual impairment in a range of retinal diseases and optic neuropathies.
SN - 1350-9462
ER -